Company / Operating Cash Flow
Barinthus Biotherapeutics plc. Operating Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$48.0M
FY2025
5-year range
-$50.9M / -$11.0M
FY2021-FY2025
Trend
+5.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 5 years, ranging from -$51M in FY2024 to -$11M in FY2021.
Based on SEC 10-K filings.
-$48M in FY2025.
Declined from -$14M to -$48M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 5.8% year-over-year.
- Peak operating cash flow was recorded in FY2021.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$48.0M | +5.8% |
| FY2024 | -$50.9M | -252.9% |
| FY2023 | -$14.4M | +55.7% |
| FY2022 | -$32.6M | -195.5% |
| FY2021 | -$11.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026